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Abstract: Reported prevalence rates of persistent postpartum pain (PPP) range from less than 
1% to almost 20%. The aim of this study was to examine the prevalence of PPP in a Dutch 
cohort and to evaluate a possible causal role for specific risk factors on the development of 
chronic pain after childbirth. A questionnaire was sent to 960 postpartum women approximately 
2 years after delivery. Primary outcome was pain that arose from childbirth at follow-up, and 
secondary outcomes included quality of life (QoL) and Hospital Anxiety and Depression Scale 
scores. Tested risk factors included mode of labor analgesia, history of negative effect, history 
of chronic pain, delivery route, parity, and ethnicity. A total of 495 (51.6%) women participated. 
At a mean time of 2.3 postpartum years, 7.3% of women reported any pain and 6.1% reported 
significant pain related to the delivery. Compared to spontaneous delivery, cesarean delivery 
provided protection against persistent pain (odds ratio, 0.12; 95% CI, 0.01–0.63, P,0.05). 
None of the other risk factors, including remifentanil use for labor pain, were of influence on 
the prevalence of persistent pain. Women with PPP experienced greater negative effects and had 
lower QoL scores compared to women without pain. In this cohort of Dutch patients, PPP is a 
serious problem with a great impact on the physical and mental health of women.
Keywords: chronic pain after childbirth, chronic pain, partus, labor analgesia, remifentanil, 
epidural analgesia, risk factors
Introduction
Both vaginal and cesarean delivery are associated with significant tissue damage. 
Vaginal deliveries are associated with uterine contractions, dilation of the cervix and 
lower uterine segment, stretching and compression of pelvic and perineal structures, 
inflammation of cervical tissue, and tears in the birth canal.1,2 During a cesarean sec-
tion (CS), tissue damage is related to the skin incision, traction on abdominal muscles 
and nerves, and incision in the lower segment of the uterus.2 Multiple studies show 
that severe pain following surgery is linked to development of chronic or persistent 
pain.3,4 Pain following childbirth is not different in this respect. The reported prevalence 
of persistent postpartum pain (PPP) in women who gave birth either vaginally or by 
CS varies from less than 1% to almost 20%.1,2,5–9 Apart from the differences in study 
samples and methods to report pain, this large range might be explained by the fact 
that most previous studies did not discriminate between preexisting and new onset pain 
from delivery.5,7,9 In contrast, Eisenach et al2 defined the primary outcome measure as 
pain which began during delivery at a location which could be attributed to the delivery 
(eg, pelvis, perineum, and abdomen). In their study, PPP after childbirth was relatively 
rare, with a prevalence of 1.8% at 6 months and 0.3% at 12 months.





In this study, we examined the prevalence of PPP in 
a cohort of Dutch women. We surveyed women who had 
participated in the RAVEL (Remifentanil patient controlled 
analgesia versus epidural analgesia during labor) trial.10 
This multicenter randomized controlled equivalence trial 
examined the effect of remifentanil patient-controlled anal-
gesia (RPCA) vs epidural analgesia (EA) for labor pain. 
Approximately 2 years after delivery, the women were queried 
about the presence of PPP as well as for signs of anxiety and 
depression. Additionally, the women were asked to recollect 
pain at 3 months after childbirth (the end of maternity leave 
in the Netherlands) and at the first birthday of the child to 
get an impression of the course of PPP. Logistic regression 
models were constructed to estimate the role of specific risk 
factors in the development of PPP. An important risk factor 
for development of postoperative persistent pain is treatment 
with remifentanil during surgery.11,12 Extrapolating these data 
to the perinatal setting leads to the hypothesis that the use of 
RPCA for labor pain may be associated with more complaints 
of PPP following childbirth compared to no analgesic treat-
ment or epidural labor analgesia.
Methods
study design and population
The RAVEL trial was registered in the Dutch Trial Register 
(http://www.trialregister.nl) under number NTR2551. Women 
who had participated in that trial received a follow-up ques-
tionnaire in July 2014.10 In that trial, 1,414 parturients who 
received secondary or tertiary obstetric care (obstetric care 
at home was excluded) in one of 15 participating  hospitals in 
the Netherlands were randomized to RPCA (30 µg bolus with 
a lockout time of 3 minutes) or EA (either with ropivacaine/
sufentanil, bupivacaine/sufentanil, levobupivacaine/sufentanil, 
or bupivacaine/fentanyl), should they ask for pain relief  during 
labor. The inclusion criteria for this follow-up study were par-
ticipation in the RAVEL trial, age .18 years, and American 
Society of Anesthesiologists (ASA) physical status I or II. 
Women were excluded for follow-up if the written informed 
consent form was not present, if there was no permission to be 
contacted for follow-up study, if no contact information was 
available, or if the child had died. Women who delivered by 
primary CS were excluded in the analysis of the RAVEL trial, 
and therefore no data were available for this follow-up study. 
The study protocol was approved by the Leiden University 
Medical Center medical ethics committee.
Data collection and outcome measures
Women received an e-mail link to the Dutch Postpartum 
Chronic Pain Questionnaire (DPCPQ) or a paper version. 
The questionnaire was designed to assess pain complaints that 
began during delivery and were still present at three specific 
times after childbirth: end of maternity leave, first birthday 
of the child, and time of the survey. The DPCPQ was made 
up of questions from specific surveys including the McGill 
Pain Questionnaire and the Hospital Anxiety and Depression 
Score (HADS),13,14 as well as additional questions aimed at the 
presence of pain before and during pregnancy and the quality 
of life (QoL). The English translation of the DPCPQ is avail-
able from the authors. Since we had access to the database of 
the RAVEL trial, specific data regarding baseline patient and 
Table 1 Baseline characteristics of the participating women
Complete  
set (n=495)







Maternal age (years; mean ± sD)a 34.6±4.5 34.6±3.9 4.4±5.0 34.8±4.6
ethnic origin: caucasian 426 167 124 112
higher education 251 96 65 73
BMi (kg/m2; mean ± sD)b 24.7±4.3 24.4±4.4 24.6±4.3 25.3±4.2
ASA classification
 1 328 128 98 87
 2 144 70 35 31
Parityc
 0 244 77 70 75
 $1 228 121c 63 43
Multiple pregnancy 24 6c 7 10
Time to follow-up (years; mean ± sD) 2.3±0.3 2.3±0.3 2.3±0.3 2.3±0.3
Notes: Data are shown as number unless otherwise indicated; aage at time of the delivery; bBMi obtained at 3 months of pregnancy; cin the group of women who did not 
receive analgesia there were significantly more multiparous women (P,0.001) and less women with a multiple pregnancy (P=0.041) compared to the women who received 
analgesia.
Abbreviations: Pca, patient-controlled analgesia; BMi, body mass index; sD, standard deviation; asa, american society of anesthesiologists.





 delivery characteristics were taken from the original RAVEL 
database. The following items were collected: pain at three 
postpartum time points, labor analgesia (RPCA, EA, or no 
analgesia), delivery route (spontaneous vaginal, instrumental 
vaginal, or CS), maternal age at delivery, body mass index 
(obtained at 3 months of pregnancy), ethnicity, ASA class, 
history of chronic pain, history of abdominal or back surgery, 
history of depression and mood disorders, parity, multiple 
pregnancy, the health-related QoL at the time of the survey 
(scored on a 10-point scale; question 18 of the DPCPQ), 
and anxiety and depression score at the time of the survey 
(derived from the HADS questionnaire). The HADS scores 
were divided into three subgroups: 0–7, 8–10, and 11–21 
points, indicating absence, possible, and probable presence 
of anxiety or depression, respectively.
The primary outcome measures were 1) pain, defined as 
pain scored on an 11-point numerical rating scale (NRS) with 
a score $1, which was present at the time of the survey and 
strictly localized at the lower back, abdomen, pelvis, vagina, 
or perianal area, and which began during delivery, and 2) 
significant pain, defined as pain as described above but with 
an NRS $3 and/or which interfered with normal daily activi-
ties, including child care, housekeeping, or work. Secondary 
outcome measures were the health-related QoL, anxiety, and 
depression scores at the time of the survey.
statistical analysis
Multivariate logistic regression was used to estimate the 
odds ratio (OR) for the occurrence of pain and significant 
pain at the time of the survey, adjusting for risk factors. To 
identify potential risk factors, univariate logistic regression 
models were fit to the data. Initial risk factors tested were 
type of labor analgesia, conversion from EA to RPCA or from 
RPCA to EA, history of depression and anxiety, history of 
chronic pain, history of back or abdominal surgery, delivery 
route, parity, and ethnicity. Those factors with a Wald test 
P-value of ,0.20 were taken into the multivariable model. 
Two separate logistic models were constructed. The first was 
on the total population, and the second was on the women 
who received either EA or RPCA.
For secondary endpoints, differences in the QoL and 
HADS scores between patients without and with significant 
pain were assessed using t-tests. The HADS score before 
childbirth was compared to the recent score with a paired 
sample t-test.
SPSS version 20 (SPSS Inc., Chicago, IL, USA) was 
used to perform the statistical analysis. P-values ,0.05 were 
considered significant.











Figure 1 Flow chart of the study.
Note: *This group includes women who received intramuscular morphine for labor 
analgesia, delivered by elective primary cesarean section, or received both types of 
analgesia consecutively during labor.
Abbreviation: Pca, patient-controlled analgesia.
Results
Of the 1,414 women enrolled in the RAVEL trial, 960 women 
did not object to participate in follow-up studies (Figure 1). 
The response rate was 51.6% (n=495; last questionnaire 
received August 18, 2014). Of these 495 women, 346 had 
a spontaneous vaginal delivery, 42 an instrumental vaginal 
delivery, 95 a (secondary) CS, and there were 12 missing 
values. The number of women treated with RPCA and EA 
for labor pain was 133 and 119, respectively; 199 women 
received no pain relief. The remaining 44 women received 
intramuscular morphine, delivered by elective primary CS, or 
received both types of analgesia consecutively during labor. 
Table 1 gives the baseline characteristics of the parturients. 
In the group of women who did not receive analgesia, there 
were significantly more multiparous women (P,0.001) and 
less women with a multiple pregnancy (P=0.04) compared 
to the women who did receive analgesia. Other items did not 
differ between treatment groups.
Prevalence of persistent pain following 
childbirth
The mean time interval from delivery to the survey was 2.3 
(SD: 0.3; range: 1.3–3.2 years). In Figure 2, the occurrence 
of PPP is given for the total population and for the three 
distinct treatment groups. At the time of the survey, 7.3% 
(95% confidence interval [CI], 5.1%–9.9%; n=35) of women 
reported any pain (NRS .0). The median NRS was 4.5, with 
an interquartile range of 4.0. Pain frequency ranged from 
daily (n=9) to near-daily pain (2–31 days without pain in the 
preceding month). There was no difference in demographics 
between women who developed pain and those who did not. 
Pain complaints were chiefly localized to the lower abdomen, 





pelvis, lower back, tailbone, vagina, perianal area, and/or 
groin. Thirty of these women (6.1%, 4.1%–8.5%) indicated 
that the pain was significant with an NRS $3 and pain affect-
ing their daily activities (eg, child care, housekeeping, and/
or work); 23 had visited a doctor because of the pain and 13 
required analgesia. In eleven women, the pain was such that 
it affected their sleep pattern.
Approximately 111 women reported PPP at the end of 
the maternity leave (22.4%; 95% CI, 18.8%–26.4%); 71 
(14.3%, 11.4%–17.7%) reported significant pain. Forty-
eight women reported that they had PPP at the first birthday 
of their child (9.7%, 7.2%–12.7%); 25 (5.1%, 3.2%–7.3%) 
had significant pain.
Logistic regression analysis showed that various fac-
tors did not reach the cutoff level of P,0.02 in the uni-
variate analysis, including history of depression and anxiety 
(negative effect), history of chronic pain, and history of back 
or abdominal surgery. The results of the analysis on the 
multivariate analysis of the complete data set are given in 
Table 2. Compared to women with no request for analgesia 
during labor, neither RPCA nor EA was a significant risk 
factor for PPP or significant PPP. Similarly, factor conver-
sion, ethnicity, parity, and assisted vaginal delivery did 
not have influence on the prevalence of PPP. Women who 
delivered via CS were protected for development of PPP 
(one of 95 women; OR: 0.13, 95% CI: 0.01–0.64, P,0.05) 
and significant PPP (one of 95 women; OR: 0.12, 95% CI: 
0.01–0.63, P,0.05) relative to women who spontaneously 
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Figure 2 Pain that began during delivery and was located in the lower back, abdomen, pelvis, vagina, or perianal area reported at the time of the survey (on average 2.3 years 
following childbirth) and retrospectively at 3 months and 1 year following childbirth.
Notes: The data are shown for the total population (A) and women who received no analgesia during labor (B), women who received remifentanil Pca during labor (C) and 
women who received epidural analgesia during labor (D). Data are mean ± upper and lower 95% confidence interval. Blue dots indicate all reported pain; orange dots indicate 
significant pain (NRS $3 and/or pain which interfered with childcare, housekeeping, or work). To guide the eye, exponential functions are fit through the data.
Abbreviations: nRs, numeric Rating scale; Pca, patient-controlled analgesia.
Table 2 Output of multivariable logistic regression model 
performed on the complete data set of 495 women
Odds ratio (95% confidence 
interval)
Pain Significant pain
Use of remifentanil Pca during  
labor vs no analgesia
0.97 (0.35–2.56) 1.22 (0.39–3.72)
Use of epidural analgesia during  
labor vs no analgesia
1.89 (0.75–2.56) 2.71 (0.99–7.74)
conversion vs no conversiona 3.20 (0.42–16.28) 3.71 (0.50–18.2)
ethnicity: caucasian vs non- 
caucasian
2.85 (0.60–10.20) 4.29 (0.90–15.51)
Parity: multiparous vs nulliparous 1.89 (0.83–4.55) –
assisted vs nonassisted vaginal  
delivery
2.00 (0.61–5.69) 1.40 (0.40–4.10)
cesarean section vs vaginal  
spontaneous delivery
0.13 (0.01–0.64)* 0.12 (0.01–0.63)*
Notes: aconversion from remifentanil Pca to epidural analgesia or epidural analgesia 
to remifentanil Pca. The notation “–” denotes not included in the model. *P,0.05.
Abbreviation: Pca, patient-controlled analgesia.





delivered (29 and 23 of 346 women had pain and significant 
pain, respectively). There was no added pain prevalence in 
women exposed to remifentanil during labor compared to 
women who received EA, with an OR of 1.95 (95% CI, 
0.71–5.30; P.0.05) for pain and 0.45 (95% CI, 0.16–1.27, 
P.0.05) for significant pain.
Qol, anxiety, and depression  
following childbirth
At an average of 2.3 years following childbirth, women with 
pain had a lower QoL score than women without pain: 7.0 
[1.1] vs 7.8 [1.1], respectively (P,0.001).
Mean anxiety scores in women with and without sig-
nificant pain were 6.6 [4.1] and 4.6 [3.1] (P=0.008), respec-
tively. Approximately 19.4% (95% CI, 8.2%–36.0%, n=7) 
of women with PPP had probable anxiety (HADS score 
11–21) vs 5.1% (3.2%–7.5%, n=23) of women without pain. 
Approximately 27.7% (14.2%–45.2%, n=10) of women with 
PPP had possible (score 7–10) or probable anxiety vs 16.5% 
(13.2%–20.3%, n=75) of women without pain (Figure 3).
Mean depression scores in women with and without signif-
icant PPP were 4.6±3.8 and 2.6±2.8 (P=0.004), respectively. 
Approximately 5.6% (95% CI, 0.7%–18.7%, n=2) of women 
with PPP had probable depression (HADS score 11–21) vs 
1.8% (0.8%–3.4%, n=8) of women without pain; 16.7% 
(6.4%–32.8%, n=6) of women with PPP had possible (score 
7–10) or probable depression vs 7.9% (5.6%–10.8%, n=36) 
without pain (Figure 3).
There were no differences in prenatal HADS scores 
between women who would develop PPP and who would not, 
with mean scores for anxiety 4.9 [2.4] (significant pain) and 
4.5 [2.9] (no pain, P=0.516) and mean scores for depression 
3.5 [2.8] (significant pain) and 2.7 [2.5] (no pain, P=0.116), 
respectively (Figure 3).
Discussion
Taken the many millions of births each year, the occurrence 
of PPP that interferes with the daily activities in even a 
small percentage of women will have a large socioeconomic 
impact. In our cohort of 495 Dutch women, significant pain 
attributed to the delivery process was present in 6.1% (any 
pain in 7.3%) of women, on average 2.3 years after child-
birth. Extrapolation of these findings to the 170,000 deliver-
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Figure 3 Distribution of haDs scores for anxiety and depression.
Notes: (A) anxiety scores: before delivery vs on average 2.3 years after delivery. (B) anxiety scores in women without vs with pain. (C) Depression scores: before vs on 
average 2.3 years after delivery. (D) Depression scores in women without vs with pain. haDs scores 0–7, 8–10, and 11–21 points indicate absence, possible, and probable 
presence of anxiety or depression, respectively.
Abbreviation: haDs, hospital anxiety and Depression scale.





10,000 women are affected yearly with significant pain.15 The 
presence of persistent pain was associated with a reduced 
health-related QoL and a fourfold higher prevalence of 
anxiety symptoms and threefold higher prevalence of neg-
ative-effect-related symptoms compared to women without 
pain. A protective effect was observed following CS, while 
none of the other risk factors influenced the prevalence of 
PPP. Importantly, treatment of labor pain with either EA or 
RPCA had no effect on the occurrence of pain. Retrospec-
tive questions in our survey revealed that the prevalence of 
significant pain at the end of maternity leave was 14.3% (any 
pain 22.4%) and at the child’s first birthday was 5.1% (any 
pain 9.7%), which indicates that no resolution occurred in 
the second year of postpartum pain.
The questions in the DPCPQ were such that the women 
were forced to restrict pain reporting to symptoms that arose 
during delivery (ie, “new” pain). The 95% lower limit of sig-
nificant pain prevalence at the time of the survey was 4.1%. 
The response rate of our survey (∼52%) was relatively low 
and may have caused an outcome bias. One possibility is that 
the women who did not respond were without any pain com-
plaints at the time of the survey. Taking this assumption into 
account, the prevalence of significant pain might be as low 
as 3.1% with a lower limit of 2.1%. This is still considerably 
higher than the recently reported prevalence rate in the study 
by Eisenach et al,2 who showed that women in the United 
States have a PPP prevalence of 0.3% at 1-year postdelivery. 
As indicated previously, Eisenach et al2 also restricted the 
analysis to “new” pain. Apart from the evident differences in 
protocols (the US study was a prospective longitudinal cohort 
trial in two tertiary centers in North Carolina and New York), 
specific circumstances surrounding the delivery process may 
differ. Eisenach et al6 showed further that the severity of acute 
pain after delivery was associated with the risk of transition 
to chronic pain. This would suggest that women in the Dutch 
cohort experienced more severe acute pain after delivery than 
women in the USA. We did not query the women regard-
ing immediate postpartum pain. The first interaction of the 
mother with her newborn child is highly emotional and we 
contend that this may have affected the mothers’ recollection 
at that moment in time. Still, there are no reasons to assume 
any differences in intra- and postpartum care between the 
two countries, and hence, any difference in acute postpartum 
pain between studies. Another possibility for the difference in 
outcome may be related to the number of CSs. The number of 
CSs was greater in the US cohort (32% vs 19%).2 Still in the 
US study, the mode of delivery did not represent a significant 
risk factor for chronic pain development, and in our study 
women who delivered predominantly by secondary CS were 
relatively protected from PPP development. Alternatively, 
and possibly most importantly, there may be biopsychoso-
cial differences surrounding delivery that may play a causal 
role in the difference in PPP development between the two 
cohorts (eg, factors related to endogenous modulation of 
pain, pain catastrophizing, coping strategies, genetics, etc). 
Future prospective studies should address which risk factors 
for chronic pain are responsible for the relatively high PPP 
rates observed in the Netherlands.
The survey was taken on average 2.3 years after delivery. 
Since the RAVEL trial was not designed to study PPP, we had 
to rely on retrospective questions to assess pain complaints at 
3 months and 1 year after childbirth, introducing a possible 
recall bias. It is likely that women who experienced pain at 
the time that they received the DPCPQ read and pondered 
the retrospective questions more thoroughly than the women 
without pain. However, by focusing on two time points, which 
most probably had a rather large impact on the women’s life 
(end of maternity leave and first birthday of the child), we 
believe that we created two windows of increased awareness 
regarding possible pain symptoms. Consequently, we contend 
that this may have increased the reliability of answers, also 
in women without pain at the time of the survey. We relate 
the small increase in significant pain from 1 to on average 
2.3 years after delivery (from 5.1% to 6.1%, Figure 2A), apart 
from the obvious recall bias, to the possibility that chronic 
pain is not a continuous symptom but fluctuates over time in 
terms of severity. These data suggest that chronic  postpartum 
pain resolution more than 1 year following childbirth is 
tedious. In future surveys, we will further monitor the course 
of pain in our cohort.
We had to reject our hypothesis that, in common 
with intraoperative use of remifentanil, obstetric RPCA 
increases the prevalence of PPP. Although we corrected for 
possible confounders, the study may have been underpow-
ered to detect a remifentanil effect. Another explanation 
may be that the remifentanil dose is an important factor in 
the development of chronic pain. The mean remifentanil 
dose in our study was 1.49 mg; much higher doses are 
given during anesthesia. This reasoning is supported by 
the reported dose-dependent impact of remifentanil anal-
gesia on the development of chronic thoracic pain after 
sternotomy.12
Somewhat unexpectedly, CS protected the women from 
PPP compared to spontaneous vaginal delivery, with just 





one woman (out of 95) with PPP following CS (OR 0.12 for 
pain and 0.13 for significant pain, Table 1). In most women, 
CS was performed under spinal or epidural anesthesia. For 
postoperative analgesia, paracetamol, opioids (eg, methadone 
or morphine), and nonsteroidal anti-inflammatory drugs were 
given in case of CS. As discussed by Eisenach et al,2 it is 
reasonable to assume that tissue injuries during surgery for 
a CS, such as traction on abdominal structures and nerves 
(eg, the ilio-inguinal and hypogastric nerves) and damage to 
the lower uterine segment, would increase the likelihood of 
PPP. In our cohort, most women who delivered by CS had 
contractions and some degree of cervical dilation (secondary 
CS occurred in 84 of 95 women), adding to the degree of 
tissue injury that could cause persistent pain. It is plausible 
that the protective effect of CS is related to the postoperative 
treatment of pain with opioid and/or EA. This reasoning is 
in agreement with the theory that severe postpartum pain is 
associated with a high probability of development of PPP,3 
and suggests that effective relief of severe pain after vaginal 
delivery, for example by EA, would reduce the prevalence 
of PPP.1
We established once more that PPP and negative effect 
are comorbid.16 While prenatal anxiety and depression scores 
were not different between women who developed PPP and 
those who did not, at the time of the survey the differences in 
HADS were significant with greater anxiety and depression 
scores and a reduced QoL in women with PPP compared to 
those without pain (Figure 3). This exemplifies the impact 
of chronic pain on the mental health of this relatively young 
population. Interestingly, we did not find a correlation 
between negative effect before delivery and the development 
of PPP. While for the transition from acute postsurgical pain 
to persistent pain this correlation is well established,17–19 this 
association is less apparent for PPP.2,7
The patient population that was targeted in our study 
included women in secondary and tertiary obstetric care. 
Since more than 20% of pregnant women in the Netherlands 
give birth in primary, midwife-led care, our results do not 
apply to the total population of Dutch pregnant women. 
Development of chronic pain in primary obstetric care 
remains unknown at present. Other limitations of the study 
included the relatively low response rate (52%) and the ret-
rospective nature of our study. Our study differs from most 
previous studies in that it, in contrast to our current study, did 
not make a distinction between pain complaints specifically 
related to childbirth and preexistent pain. Taken together, 
we contend that despite some limitations our study shows 
that persistent significant “new” pain following childbirth in 
this Dutch cohort is a serious problem with a relatively high 
prevalence at 2 years postpartum.
Conclusion
We retrospectively surveyed women on the prevalence of 
persistent pain following childbirth that began during deliv-
ery. We observed that in 495 women, at a mean time of 2.3 
postpartum years, 6.1% complained of significant pain related 
to delivery. Compared to spontaneous delivery, cesarean 
delivery provided protection against persistent pain. Our 
results further show important implications for the physical 
and mental health of the women in pain.
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